Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Receivables: 2010-2025

Historic Receivables for Altimmune (ALT) over the last 14 years, with Sep 2025 value amounting to $1.5 million.

  • Altimmune's Receivables rose 112.23% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 17.26%. This contributed to the annual value of $944,000 for FY2024, which is 22.05% down from last year.
  • Latest data reveals that Altimmune reported Receivables of $1.5 million as of Q3 2025, which was up 381.31% from $321,000 recorded in Q2 2025.
  • Over the past 5 years, Altimmune's Receivables peaked at $4.8 million during Q1 2021, and registered a low of $136,000 during Q2 2023.
  • In the last 3 years, Altimmune's Receivables had a median value of $728,000 in 2024 and averaged $741,000.
  • Per our database at Business Quant, Altimmune's Receivables slumped by 95.98% in 2022 and then soared by 600.00% in 2023.
  • Over the past 5 years, Altimmune's Receivables (Quarterly) stood at $429,000 in 2021, then crashed by 59.67% to $173,000 in 2022, then soared by 600.00% to $1.2 million in 2023, then dropped by 22.05% to $944,000 in 2024, then spiked by 112.23% to $1.5 million in 2025.
  • Its Receivables stands at $1.5 million for Q3 2025, versus $321,000 for Q2 2025 and $907,000 for Q1 2025.